Oligonucleotide Therapeutics Society

Recent Articles

Recent Articles2026-08-24T06:57:48+00:00
22April, 2022

A Novel Cocktail Drug Penetrates Heart Muscle and May Treat Nearly Half of All Patients with DMD

Duchenne muscular dystrophy (DMD) is a devastating disease that causes the body's muscle tissues to progressively waste away until all mobility is lost. Eventually, the heart muscle becomes fatty and fibrotic, typically leading to heart failure and death by age 30. There is no cure, and the approved drugs ...

9March, 2022

Support for Ukrainian Scientists

The OTS joins other scientific organizations in seeking to help Ukrainian scientists. Specifically, we invite Ukrainian students, scientists, and industry professionals with interests in the field of nucleic acids and oligonucleotide therapeutics to post their contact information and CVs on the OTS website. We ask our membership to spread ...

28February, 2022

A New ASO Shows Promise in Treating Dravet Syndrome, a Severe Form of Epilepsy

 Typically, a single copy of a gene is enough to support normal growth and development but in a small subset of genes, the loss of one copy can cause serious diseases that are often difficult to treat. One of these conditions, Dravet Syndrome, has no treatment options that directly target ...

9February, 2022

A Potent ASO Shows Encouraging Results in A Single-Patient Pilot Study for ALS

 Amyotrophic lateral sclerosis (ALS) is a progressive, neurodegenerative disease in which motor neurons die. Since the motor neurons that die control voluntary muscles, the disease causes great difficulty for those who must live with it. They will experience loss of motor control of the arms and legs which causes them ...

24December, 2021

Looking back… Looking forward

This will be my last contribution that I write as President of our Society. On January 1st, 2022, I will become ‘Immediate Past-President’. David Corey (University of Texas, Southwestern) will take over as President and Richard Geary (Ionis Pharmaceuticals) will become the Society’s next President-Elect. As we delayed this ...

10November, 2021

IKARIA – An Innovative Platform that Yields Long-Acting siRNA

In this year that marks the 20th Anniversary of the discovery of RNA interference as a gene-silencing mechanism in mammalian cells, Alnylam announced another remarkable development in siRNA therapeutics – a platform that could allow for administration of siRNA medications just once a year with highly potent knockdown of ...

A New ASO Shows Promise in Treating Dravet Syndrome, a Severe Form of Epilepsy

February 28th, 2022|Categories: Perspectives on Current Science|

 Typically, a single copy of a gene is enough to support normal growth and development but in a small subset of genes, the loss of one copy can cause serious ...

Comments Off on A New ASO Shows Promise in Treating Dravet Syndrome, a Severe Form of Epilepsy

A Potent ASO Shows Encouraging Results in A Single-Patient Pilot Study for ALS

February 9th, 2022|Categories: Perspectives on Current Science|

 Amyotrophic lateral sclerosis (ALS) is a progressive, neurodegenerative disease in which motor neurons die. Since the motor neurons that die control voluntary muscles, the disease causes great difficulty for those ...

Comments Off on A Potent ASO Shows Encouraging Results in A Single-Patient Pilot Study for ALS

IKARIA – An Innovative Platform that Yields Long-Acting siRNA

November 10th, 2021|Categories: Perspectives on Current Science|

In this year that marks the 20th Anniversary of the discovery of RNA interference as a gene-silencing mechanism in mammalian cells, Alnylam announced another remarkable development in siRNA therapeutics ...

Comments Off on IKARIA – An Innovative Platform that Yields Long-Acting siRNA

Get the latest news!

  • Category

Go to Top